AMO-1 Cells
General information
| Description | The AMO-1 cell line is a multiple myeloma model derived from a malignant plasma cell neoplasm. It is extensively used in research exploring mechanisms of drug sensitivity, apoptosis, and tumor cell signaling in myeloma. AMO-1 cells are sensitive to various chemotherapeutic agents and targeted treatments, such as proteasome inhibitors and tyrosine kinase inhibitors, which have become crucial in multiple myeloma therapy. Studies have demonstrated that treatment with spleen tyrosine kinase (Syk) inhibitors induces significant anti-proliferative and pro-apoptotic effects in AMO-1 cells. This action occurs through inhibition of critical signaling pathways, including MAPK and NF-kappaB, and is characterized by increased cytochrome c release and activation of apoptotic markers like caspase-3 and PARP-1. Additionally, Syk inhibition reduces cell migration and interaction with bone marrow stromal components, further limiting myeloma cell survival. AMO-1 cells have also shown susceptibility to natural compounds targeting the Notch3-p53 axis, such as sophocarpine derivatives. These compounds reduce cell viability by downregulating anti-apoptotic proteins (e.g., Bcl-2) and upregulating pro-apoptotic factors (e.g., Bax and cleaved caspase-3). Moreover, sophocarpine treatment decreases Notch3 expression, a pathway linked to tumor progression in myeloma and other cancers. This makes AMO-1 an effective model for testing drugs aimed at modifying Notch signaling and the apoptotic pathways mediated by p53. In immunotherapy contexts, AMO-1 cells are recognized by γδ T cells through the expression of intercellular adhesion molecule-1 (ICAM-1), and transfection to increase ICAM-1 expression enhances their susceptibility to T cell-mediated lysis. This characteristic supports studies into myeloma-targeted immunotherapies as an alternative approach to treatment-resistant cases. |
|---|---|
| Organism | Human |
| Tissue | Ascites |
| Disease | Multiple myeloma |
| Synonyms | AMo1, AMO1 |
Characteristics
| Age | 64 years |
|---|---|
| Gender | Female |
| Ethnicity | Japanese |
| Morphology | Round cells |
| Growth properties | Suspension |
Regulatory Data
| Citation | AMO-1 (Cytion catalog number 305525) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1806 |
Biomolecular Data
| Mutational profile | Gene fusion: IGKV1-8-IGKJ1; Gene fusion: IGKV3-20-IGKJ2; Mutation: BCOR, p.Gln312del (c.932_934AGC[1]) (c.935_937delAGC), heterozygous; Mutation: KRAS, p.Ala146Thr (c.436G>A), heterozygous; Mutation: STAT3, p.Cys712Tyr (c.2135G>A), heterozygous; Mutation: TET2, p.Gln1699Ter (c.5095C>T), heterozygous |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 20% FBS |
| Subculturing | Gather the suspension cells in a 15 ml tube and gently wash the adherent cells with PBS lacking calcium and magnesium (use 3-5 ml for T25 flasks and 5-10 ml for T75 flasks). Apply Accutase (1-2 ml for T25 flasks, 2.5 ml for T75 flasks) ensuring full coverage of the cell layer. Allow the cells to incubate at room temperature for 10 minutes. Following incubation, combine and centrifuge both the suspension and adherent cells. After centrifugation, carefully resuspend the cell pellet and transfer the cell suspension into new flasks containing fresh medium. |
| Seeding density | 3-5*10^5/ml |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|